Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.02 USD
Change Today +0.21 / 3.08%
Volume 3.4M
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (ARIA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/15 - $10.07
52 Week Low
10/13/14 - $4.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ariad pharmaceuticals inc (ARIA) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (ARIA) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (ARIA) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $676.0K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $858.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $683.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $647.0K
Compensation as of Fiscal Year 2014.

ariad pharmaceuticals inc (ARIA) Key Developments

Ariad Pharmaceuticals Inc. Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib

ARIAD Pharmaceuticals Inc. announced that it has achieved full enrollment in the pivotal Phase 2 ALTA trial of its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib. This registration study enrolled approximately 220 patients at approximately 75 sites in North America, Europe and Asia. The company expects data from this trial to form the basis for an NDA filing of brigatinib in patients with refractory non-small cell lung cancer in the third quarter of 2016. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of brigatinib (previously known as AP26113) in refractory non-small cell lung cancer (NSCLC) patients who test positive for the ALK oncogene (ALK+) and who have been treated with and progressed on their most recent crizotinib therapy. The primary endpoint of the trial is objective response rate (ORR) as measured by RECIST criteria. Brigatinib received Breakthrough Therapy designation from the U.S. Food and Drug Administration in 2014. Median time on treatment for patients in the ALTA trial is less than 4 months, and follow-up data are limited at this time. As a result, ARIAD now expects that first data from the trial will be submitted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting in 2016. Presenting data at ASCO will also align more closely with the anticipated filing for marketing approval of brigatinib in the U.S. in the third quarter of 2016. A randomized front-line clinical trial of brigatinib is expected begin in early 2016. This Phase 3 trial will compare brigatinib to crizotinib in approximately 300 patients with ALK+ NSCLC, who have not received prior ALK inhibitors.

Baxalta Is Said To Abandon Takeover Talks With Ariad

Baxalta Incorporated (NYSE:BXLT) has abandoned its pursuit of Ariad Pharmaceuticals Inc. (NasdaqGS:ARIA) after negotiations broke down over price, people with knowledge of the matter said. Talks between Baxalta and Ariad ended earlier this week and there are currently no plans to resume negotiations, the people said, asking not to be identified as the matter is private. A spokeswoman for Ariad declined to comment, while representatives for Baxalta didn’t immediately respond to a phone call and e-mail seeking comment, reported Bloomberg.

Baxalta Reportedly In Talks To Buy Ariad

Baxalta Incorporated (NYSE:BXLT) is in talks to buy Ariad Pharmaceuticals Inc. (NasdaqGS:ARIA), people with knowledge of the matter said.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $7.02 USD +0.21

ARIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $5.09 USD +0.13
Evotec AG €4.13 EUR +0.009
Exelixis Inc $5.99 USD +0.135
Infinity Pharmaceuticals Inc $8.37 USD +0.48
Insys Therapeutics Inc $25.65 USD +0.64
View Industry Companies

Industry Analysis


Industry Average

Valuation ARIA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at